MicroRNA-214 promotes apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Heishima, Kazuki ^a   Mori, Takashi ^a   Sakai, Hiroki ^a   Sugito, Nobuhiko ^a   Murakami, Mami ^a   Yamada, Nami ^a   Akao, Yukihiro ^a   Maruo, Kohji ^a  

^a GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 214; PROTEIN P53; UBIQUITIN PROTEIN LIGASE COP1; 3' UNTRANSLATED REGION; MESSENGER RNA; MICRORNA; RNA; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOG; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSFECTION; HEMANGIOSARCOMA CELL LINE; NONHUMAN; PROTEIN RNA BINDING; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL LINE; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; 3' UNTRANSLATED REGION; ANIMAL; BIOSYNTHESIS; CELL CYCLE; CELL DIVISION; DOG DISEASE; FEMALE; GENETICS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; REPORTER GENE; RNA INTERFERENCE; TUMOR CELL LINE; VETERINARY;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEMANGIOSARCOMA; MALE; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84945318637     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137361     Document Type: Article

References (51)

1. Rouhani P, Fletcher CD, Devesa SS, Toro JR. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12, 114 cases. Cancer. 2008; 113(3):616-27. doi: 10.1002/cncr.23571 PMID: 18618615.
2. Donnell RM, Rosen PP, Lieberman PH, Kaufman RJ, Kay S, Braun DW Jr., et al. Angiosarcoma and other vascular tumors of the breast. Am J Surg Pathol. 1981; 5(7):629-42. PMID: 7199829.
3. Blanchard DK, Reynolds C, Grant CS, Farley DR, Donohue JH. Radiation-induced breast sarcoma. Am J Surg. 2002; 184(4):356-8. PMID: 12383902.
4. Tate G, Suzuki T, Mitsuya T. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet. 2007; 178(2):160-2. doi: 10.1016/j.cancergencyto.2007.07.017 PMID: 17954274.
5. Anoun S, Marouane S, Quessar A, Benchekroun S. Primary Splenic Angiosarcoma Revealed by Bone Marrow Metastasis. Turk J Haematol. 2014; 31(4):408-10. doi: 10.4274/tjh.2013.0049 PMID: 25541659.
6. Fayette J, Martin E, Piperno-Neumann S, Le Cesne A, Robert C, Bonvalot S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol. 2007; 18(12):2030-6. doi: 10.1093/annonc/mdm381 PMID: 17974557.
7. Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, et al. Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007; 14(6):1953-67. doi: 10.1245/ s10434-006-9335-y PMID: 17356953.
8. Coindre JM, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchere D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001; 91(10):1914-26. doi: 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO;2-3 PMID: 11346874.
9. Ogilvie GK, Powers BE, Mallinckrodt CH, Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. J Vet Intern Med. 1996; 10(6):379-84. PMID: 8947871.
10. Dorn CR, Taylor DO, Frye FL, Hibbard HH. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. I. Methodology and description of cases. J Natl Cancer Inst. 1968; 40(2):295-305. PMID: 5694271.
11. Gamlem H, Nordstoga K, Arnesen K. Canine vascular neoplasia-a population-based clinicopathologic study of 439 tumours and tumour-like lesions in 420 dogs. Apmis. 2008; 116(125):41-54. doi: 10.1111/ j.1600-0463.2008.125m4.x
12. Khanna C, Lindblad-Toh K, Vail D, London C. The dog as a cancer model. Nature. 2006.
13. Goga A, Benz C. Anti-oncomir suppression of tumor phenotypes. Mol Interv. 2007; 7(4):199-202, 180. doi: 10.1124/mi.7.4.6 PMID: 17827440.
14. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008; 79(4):581-8. doi: 10.1093/cvr/cvn156 PMID: 18550634.
15. Sharma T, Hamilton R, Mandal CC. miR-214: a potential biomarker and therapeutic for different cancers. Future Oncol. 2015; 11(2):349-63. doi: 10.2217/fon.14.193 PMID: 25591843.
16. van Mil A, Grundmann S, Goumans MJ, Lei Z, Oerlemans MI, Jaksani S, et al. MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release. Cardiovasc Res. 2012; 93(4):655-65. doi: 10.1093/cvr/cvs003 PMID: 22227154.
17. Derfoul A, Juan AH, Difilippantonio MJ, Palanisamy N, Ried T, Sartorelli V. Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis. 2011; 32(11):1607-14. doi: 10.1093/carcin/ bgr184 PMID: 21828058; PubMed Central PMCID: PMC3204346.
18. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 7. J Biol Chem. 2012; 287(17):14301-9. doi: 10.1074/jbc.M111.337642 PMID: 22399294; PubMed Central PMCID: PMC3340176.
19. Wang F, Liu M, Li X, Tang H. MiR-214 reduces cell survival and enhances cisplatin-induced cytotoxicity via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett. 2013; 587(5):488-95. doi: 10.1016/j. febslet.2013.01.016 PMID: 23337879.
20. Duan Q, Wang X, Gong W, Ni L, Chen C, He X, et al. ER stress negatively modulates the expression of the miR-199a/214 cluster to regulates tumor survival and progression in human hepatocellular cancer. PLoS One. 2012; 7(2):e31518. doi: 10.1371/journal.pone.0031518 PMID: 22359598; PubMed Central PMCID: PMC3281082.
21. Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, et al. MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 2012; 57(3):584-91. doi: 10.1016/j.jhep.2012.04.031 PMID: 22613005.
22. Li B, Han Q, Zhu Y, Yu Y, Wang J, Jiang X. Down-regulation of miR-214 contributes to intrahepatic cholangiocarcinoma metastasis by targeting Twist. FEBS J. 2012; 279(13):2393-8. doi: 10.1111/j.1742- 4658.2012.08618.x PMID: 22540680.
23. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28(10):1385-92. doi: 10.1038/onc.2008.474 PMID: 19137007.
24. Long LM, He BF, Huang GQ, Guo YH, Liu YS, Huo JR. microRNA-214 functions as a tumor suppressor in human colon cancer via the suppression of ADP-ribosylation factor-like protein 2. Oncol Lett. 2015; 9 (2):645-50. doi: 10.3892/ol.2014.2746 PMID: 25621032; PubMed Central PMCID: PMC4301474.
25. Zhao Z, Tan X, Zhao A, Zhu L, Yin B, Yuan J, et al. microRNA-214-mediated UBC9 expression in glioma. BMB Rep. 2012; 45(11):641-6. doi: 10.5483/BMBRep.2012.45.11.097 PMID: 23187003; PubMed Central PMCID: PMC4133799.
26. Misiewicz-Krzeminska I, Sarasquete ME, Quwaider D, Krzeminski P, Ticona FV, Paino T, et al. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica. 2013; 98(4):640-8. doi: 10.3324/haematol.2012. 070011 PMID: 23100276; PubMed Central PMCID: PMC3659997.
27. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013; 8(10): e76994. doi: 10.1371/journal.pone.0076994 PMID: 24167554; PubMed Central PMCID: PMC3805541.
28. Wang J, Zhang X, Wang L, Yang Y, Dong Z, Wang H, et al. MicroRNA-214 Suppresses Oncogenesis and Exerts Impact on Prognosis by Targeting PDRG1 in Bladder Cancer. PLoS One. 2015; 10(2): e0118086. doi: 10.1371/journal.pone.0118086 PMID: 25706919; PubMed Central PMCID: PMC4338228.
29. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, Wagner I, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013; 15(5):695-705. doi: 10.1016/j.jmoldx.2013.05.008 PMID: 23945108.
30. Huang HJ, Liu J, Hua H, Li SE, Zhao J, Yue S, et al. MiR-214 and N-ras regulatory loop suppresses rhabdomyosarcoma cell growth and xenograft tumorigenesis. Oncotarget. 2014; 5(8):2161-75. PMID: 24811402; PubMed Central PMCID: PMC4039153.
31. Shen J, Yang X, Xie B, Chen Y, Swaim M, Hackett SF, et al. MicroRNAs regulate ocular neovascularization. Mol Ther. 2008; 16(7):1208-16. doi: 10.1038/mt.2008.104 PMID: 18500251; PubMed Central PMCID: PMC3033219.
32. Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur J Pharm Sci. 2009; 38(4):370-7. doi: 10.1016/j.ejps.2009.08.008 PMID: 19733659.
33. Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat Res. 2009; 681(2-3):118-33. doi: 10.1016/j.mrrev.2008.06.002 PMID: 18639648.
34. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991; 253(5015):49-53. doi: 10.1126/science.1905840 PMID: 1905840.
35. van Leeuwen IS, Cornelisse CJ, Misdorp W, Goedegebuure SA, Kirpensteijn J, Rutteman GR. P53 gene mutations in osteosarcomas in the dog. Cancer Lett. 1997; 111(1-2):173-8. PMID: 9022143.
36. Yonemaru K, Sakai H, Murakami M, Kodama A, Mori T, Yanai T, et al. The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma. J Vet Med Sci. 2007; 69(3):271-8. doi: 10.1292/ jvms.69.271 PMID: 17409643.
37. Italiano A, Chen CL, Thomas R, Breen M, Bonnet F, Sevenet N, et al. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics. Cancer. 2012; 118(23):5878-87. doi: 10.1002/cncr.27614 PMID: 22648906; PubMed Central PMCID: PMC3434269.
38. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997; 387 (6630):296-9. doi: 10.1038/387296a0 PMID: 9153395.
39. Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, Sturzl M, et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol. 1998; 153 (5):1425-33. doi: 10.1016/S0002-9440(10)65729-X PMID: 9811333; PubMed Central PMCID: PMC1876718.
40. Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004; 429(6987):86-92. doi: 10.1038/nature02514 PMID: 15103385.
41. Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 2010; 70 (21):8264-9. doi: 10.1158/0008-5472.CAN-10-0749 PMID: 20959491; PubMed Central PMCID: PMC2970744.
42. Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004; 64(20):7226-30. doi: 10.1158/0008-5472.CAN-04-2601 PMID: 15492238.
43. Murai A, Asa SA, Kodama A, Hirata A, Yanai T, Sakai H. Constitutive phosphorylation of the mTORC2/ Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res. 2012; 8:128. doi: 10.1186/1746-6148-8-128 PMID: 22839755; PubMed Central PMCID: PMC3438112.
44. Yamada N, Tsujimura N, Kumazaki M, Shinohara H, Taniguchi K, Nakagawa Y, et al. Colorectal cancer cell-derived microvesicles containing microRNA-1246 promote angiogenesis by activating Smad 1/5/8 signaling elicited by PML down-regulation in endothelial cells. Biochim Biophys Acta. 2014; 1839 (11):1256-72. doi: 10.1016/j.bbagrm.2014.09.002 PMID: 25218966.
45. Taniguchi K, Ito Y, Sugito N, Kumazaki M, Shinohara H, Yamada N, et al. Organ-specific PTB1-associated microRNAs determine expression of pyruvate kinase isoforms. Sci Rep. 2015; 5:8647. doi: 10. 1038/srep08647 PMID: 25721733; PubMed Central PMCID: PMC4342556.
46. Peters IR, Peeters D, Helps CR, Day MJ. Development and application of multiple internal reference (housekeeper) gene assays for accurate normalisation of canine gene expression studies. Vet Immunol Immunopathol. 2007; 117(1-2):55-66. doi: 10.1016/j.vetimm.2007.01.011 PMID: 17346803.
47. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1):15-20. doi: 10.1016/j.cell.2004. 12.035 PMID: 15652477.
48. Wang X. miRDB: a microRNA target prediction and functional annotation database with a wiki interface. RNA. 2008; 14(6):1012-7. doi: 10.1261/rna.965408 PMID: 18426918; PubMed Central PMCID: PMC2390791.
49. Wang X, El Naqa IM. Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 2008; 24(3):325-32. doi: 10.1093/bioinformatics/btm595 PMID: 18048393.
50. Lynam-Lennon N, Maher SG, Reynolds JV. The roles of microRNA in cancer and apoptosis. Biol Rev Camb Philos Soc. 2009; 84(1):55-71. doi: 10.1111/j.1469-185X.2008.00061.x PMID: 19046400.
51. Yang Z, Chen S, Luan X, Li Y, Liu M, Li X, et al. MicroRNA-214 is aberrantly expressed in cervical cancers and inhibits the growth of HeLa cells. IUBMB Life. 2009; 61(11):1075-82. doi: 10.1002/iub.252 PMID: 19859982.